Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603615 · ClinicalTrials.gov registry record · Phase 3
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT01603615 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 220 participants.
The verdict
NCT01603615, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.
Interventions
- BIOLOGICAL Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2012-10-30 |
| Est. Completion | 2018-09-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01603615
The ClinicalTrials.gov registry entry for NCT01603615 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum Toxin Type A is the first listed.
NCT01603615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01603615 about?
NCT01603615 is a clinical study titled "BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity". This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.
What is the current status of trial NCT01603615?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2012-10-30. Estimated completion is 2018-09-03.
What interventions are being tested in trial NCT01603615?
The interventions under investigation include: Botulinum Toxin Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01603615?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.